Abstract

Mayo Clinic Cancer Center (MCCC) CCSG Senior Leadership includes the Director, Deputy Director at Large, Deputy Director Clinical Research, Deputy Director Arizona, Deputy Director Florida, Deputy Director Administration, and 3 Associate Directors. There have been a number of changes since the last renewal. Given the size, complexity and geographical locations of our Cancer Center, a Deputy Director at Large was added to aid in the integration of our 3 site Cancer Center. Dr. Edith Perez currently serves in this role. Dr. Ruben Mesa has replaced Dr. Rafael Fonseca as Deputy Director MCCC Arizona as Dr. Fonseca stepped down to assume leadership responsibilities as Chair, Department of Medicine, Mayo Clinic in Arizona. Mr. Brian Nelson has replaced Mr. Michael Pfenning as senior administrator for MCCC. Mr. Pfenning stepped down to assume other leadership responsibilities at Mayo Clinic following 18 years with MCCC. To reflect the size and complexity of MCCC, Mr. Nelson assumed the role of Deputy Director Administration. Dr. Dan Billadeau replaced Dr. Edward Leof as Associate Director for Basic Science. Dr. Steven Russell replaced Dr. Robert Jenkins as Associate Director for Translational Research. Senior Leadership remaining unchanged are Dr. Robert Diasio, Director, Dr. Charies Erlichman, Deputy Director Clinical Research, Dr. Robert Smallridge, Deputy Director Florida, Dr. Gloria Petersen, Associate Director Population Sciences.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-44
Application #
9554070
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications